

BUY TP: Rs 4,660 | △ 26%

TATA CONSULTANCY SERVICES

Technology & Internet

12 April 2022

Resilient margins

- Q4 revenue growth at 3.2% QoQ CC beat consensus expectations of 2.3% but came in a tad lower than our estimate
- EBIT margin held strong at 25%, ahead of our estimate, aiding an operating profit beat; order book at all-time high of US\$ 11.3bn
- We trim FY23/FY24 EPS by 0.8%/2.6% and roll over to a new TP of Rs 4,660 (vs. Rs 4,770); retain BUY given strong demand and deal wins

Ruchi Burde | Seema Nayak researchreport@bobcaps.in

Growth underperforms: TCS's Q4FY22 revenue grew 2.6% QoQ USD, below our estimate of 3.7%. The growth was led by the telecom and media vertical (+5.8% QoQ USD), followed by retail/manufacturing (+4.7%/+3.7%). BFSI grew by a mere 2%. Among major geographies, revenue from North America increased 4.5% QoQ USD and MEA delivered impressive growth at 8%. Among the major demand drivers were cloud, consulting, cognitive business operations, cyber security, IoT and digital engineering, and TCS Interactive. The company added 13 clients QoQ in the US\$ 10mn+/20mn+ revenue buckets and 2 in the US\$ 50mn+ bucket. Net profit grew 1.6% QoQ USD.

Margin shines: TCS reported a stable EBIT margin QoQ at 25%, outperforming our estimate of 24.3% amid a tight supply environment marked by rising attrition as well as elevated hiring. The company saw only a 90bps QoQ impact from the supply crunch which was offset by operational efficiency despite peak attrition levels of 17.4%. TCS hired more than 35,000 employees in Q4FY22, its highest quarterly figure. SG&A expenses were up 20bps QoQ and subcontracting expenses increased 30bps while travel was down 40bps. The company will effect salary hikes from Apr'22, at levels slightly more than its last round of hikes.

Record deal wins: TCS reported a record TCV of US\$ 11.3bn (including two mega deals), with US\$ 8.2bn from BFSI and US\$ 2.6bn from retail. North America had an order book of US\$ 6.1bn in Q4. Ignio signed 36 new clients during the quarter. Cloud adoption in both Horizon I and Horizon II (deals based on cloud-native initiatives) have led to multiple contract wins. Deal pricing has been flattish QoQ but has improved on a full-year basis.

Other takeaways: Europe saw 6%+ growth in Q3 which has normalised due to the high base. TCS plans to announce a new organisation structure with business groups instead of verticals and service lines. It announced final dividend of Rs 22/sh in Q4.

Retain BUY: We tweak estimates to factor in the results and roll valuations to Jun'24, leading to a new TP of Rs 4,660 (vs. Rs 4,770), set at an unchanged 36.5x P/E.

Key changes

Target	Rating	
V	< ▶	

Ticker/Price	TCS IN/Rs 3,696
Market cap	US\$
Free float	28%
3M ADV	US\$ 145.9mn
52wk high/low	Rs 4,043/Rs 3,004
Promoter/FPI/DII	72%/17%/11%

Source: NSE | Price as of 11 Apr 2022

Key financials

Y/E 31 Mar	FY21A	FY22E	FY23E
Total revenue (Rs mn)	1,641,770	1,917,540	2,182,282
EBITDA (Rs mn)	465,460	530,570	607,976
Adj. net profit (Rs mn)	336,480	383,270	437,015
Adj. EPS (Rs)	90.9	103.6	118.1
Consensus EPS (Rs)	90.9	107.2	119.2
Adj. ROAE (%)	39.2	43.3	43.2
Adj. P/E (x)	40.6	35.7	31.3
EV/EBITDA (x)	29.7	26.1	22.8
Adj. EPS growth (%)	5.5	13.9	14.0

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE





Fig 1 - Quarterly performance

(Rs mn)	Q4FY22	Q4FY21	YoY (%)	Q3FY22	QoQ (%)	FY22	FY21	YoY (%)
Revenue (US\$ mn)	6,696	5,989	11.8	6,524	2.6	25,707	22,174	15.9
Revenue	505,910	437,050	15.8	488,850	3.5	1,917,540	1,641,770	16.8
Operating Expenditure	367,460	309,040	18.9	354,520	3.7	1,386,970	1,176,310	17.9
Cost of revenues	293,640	248,600	18.1	284,010	3.4	1,110,530	940,530	18.1
as % of sales	58.0	56.9	-	58.1	-	232	229	-
SG&A expenses	73,820	60,440	22.1	70,510	4.7	276,440	235,780	17.2
as % of sales	14.6	13.8	-	14.4	-	58	58	-
EBITDA	138,450	128,010	8.2	134,330	3.1	530,570	465,460	14.0
Depreciation	12,170	10,670	14.1	11,960	1.8	46,040	40,650	13.3
EBIT	126,280	117,340	7.6	122,370	3.2	484,530	424,810	14.1
Other Income	7,360	7,930	(7.2)	9,540	(22.9)	32,340	24,970	-
PBT	133,640	125,270	6.7	131,910	1.3	516,870	449,780	14.9
Total Tax	34,050	32,450	4.9	33,850	0.6	132,380	111,980	18.2
Adjusted PAT	99,590	92,820	7.3	98,060	1.6	384,490	337,800	13.8
(Profit)/loss from JV's/Ass/MI	(330)	(360)	-	(370)	-	(1,220)	(1,320)	-
APAT after MI	99,260	92,460	7.4	97,690	1.6	383,270	336,480	13.9
Reported PAT	99,260	92,460	7.4	97,690	1.6	383,270	336,480	13.9
Reported EPS	26.8	25.0	7.4	26.4	1.6	104	90	15.1
Margins (%)			(bps)		(bps)			(bps)
EBITDA	27.4	29.3	(190)	27.5	(10)	27.7	28.4	70
EBIT	25.0	26.8	(190)	25.0	(10)	25.3	25.9	60
EBT	26.4	28.7	(220)	27.0	(60)	27.0	27.4	40
PAT	19.6	21.2	(150)	20.0	(40)	20.0	20.5	50
Effective Tax rate	25.5	25.9	(40)	25.7	(20)	25.6	24.9	(70)
Course: Company, POPCARS Research								

Source: Company, BOBCAPS Research

Fig 2 - Operating metrics

(: LIC¢ +)	Q4FY22	Growth (%)			
(in US\$ terms)	(% Contr. to Revenue)	QoQ	YoY		
Deal win TCV (US\$ mn)	11,300	48.7	22.8		
Revenue by Geography					
Americas	51.6	4.5	18.7		
UK	15.6	2.6	9.0		
Europe	15.5	(0.6)	3.2		
India	5.1	(4.8)	1.8		
Asia Pac	8.5	1.4	1.1		
Ibero America	1.7	2.6	2.0		
MEA	2.0	8.0	11.8		
Revenue by Domain					
BFSI	31.9	2.0	10.8		
Manufacturing	10.0	3.7	16.5		
Telecom & Media	6.7	5.8	15.2		
Life Sciences & Healthcare	10.0	3.7	15.3		
Retail & CPG	15.4	4.7	18.7		
Technology & Services	8.7	2.6	15.8		
Regional Markets & Others	17.3	(0.2)	1.3		

	Q4FY22	Q3FY22	Q4FY21
Attrition (LTM) (%)	17.4	15.3	7.2

Source: Company, BOBCAPS Research



Valuation methodology

We trim our FY22/FY23/FY24 EPS estimates by 1.8%/0.8%/2.6% to bake in the Q4FY22 results while keeping our target P/E unchanged at 36.5x. On rolling valuations over to Jun'24, we have a new TP of Rs 4,660 (vs. Rs 4,770 earlier). Maintain BUY on strong deal wins and a robust demand environment.

Fig 3 - Revised estimates

(Pa mn)		New			Old			Change (%)	
(Rs mn)	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenues (US\$ mn)	25,707	28,816	31,996	25,776	29,114	32327	(0.3)	(1.0)	(1.0)
YoY growth (%)	15.9	12.1	11.0	16.2	12.9	11.0	-	-	-
Revenues	1,917,540	2,182,282	2,431,676	1,921,740	2,204,897	2456875	(0.2)	(1.0)	(1.0)
EBITDA	530,570	607,976	680,189	527,299	614,276	687237	0.6	(1.0)	(1.0)
EBITDA margin (%)	27.7	27.9	28.0	27.4	27.9	28.0	-	-	-
EBIT margin (%)	25.3	25.6	26.3	25.7	25.7	26.4	(40bps)	(10bps)	0bps
Net profits	383,270	437,015	491,275	390,221	440,707	504365	(1.8)	(0.8)	(2.6)
EPS (Rs)	103.6	118.1	132.8	105.5	119.1	136.3	(1.8)	(0.8)	(2.6)

Source: BOBCAPS Research

Key risks

Key downside risks to our estimates are:

- rising attrition impacting margins, and
- demand-supply mismatch resulting in lost revenue.

Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Coforge	COFORGE IN	3.5	4,312	7,080	BUY
eClerx Services	ECLX IN	1.2	2,439	3,790	BUY
HCL Technologies	HCLT IN	40.5	1,134	1,610	BUY
Infosys	INFO IN	99.0	1,767	2,250	BUY
L&T Infotech	LTI IN	14.0	6,060	8,490	BUY
Mindtree	MTCL IN	9.2	4,232	5,610	BUY
Mphasis	MPHL IN	7.7	3,129	3,470	HOLD
Persistent Systems	PSYS IN	4.8	4,515	4,580	HOLD
Tata Consultancy Services	TCS IN	182.6	3,696	4,660	BUY
Tech Mahindra	TECHM IN	16.6	1,449	1,940	BUY
Wipro	WPRO IN	41.5	571	850	BUY

Source: BOBCAPS Research, NSE | Price as of 11 Apr 2022



Financials

Income Statement					
Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Total revenue	1,569,490	1,641,770	1,917,540	2,182,282	2,431,676
EBITDA	421,100	465,460	530,570	607,976	680,189
Depreciation	35,300	40,650	46,040	49,170	40,227
EBIT	385,800	424.810	484,530	558,806	639,961
Net interest inc./(exp.)	0	0	0	0	0
Other inc./(exp.)	36,680	24,970	32,340	29,403	27,884
Exceptional items	0	0	02,010	0	0
EBT	422,480	449,780	516,870	588,208	667,846
Income taxes	98,010	111,980	132.380	149,993	175,370
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	(1,070)	(1,320)	(1,220)	(1,200)	(1,200)
Reported net profit	323,400	336,480	383,270	437,015	491,275
Adjustments	0	0	0	0	0
Adjusted net profit	323,400	336,480	383,270	437,015	491,275
rajacica not prom	020, 100	330,100	000,2.0	,	,
Balance Sheet					
Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Accounts payables	0	0	0	0	0
Other current liabilities	292,440	371,480	453,000	376,668	419,714
Provisions	0	0	0	0	0
Debt funds	69,060	65,030	63,680	63,680	63,680
Other liabilities	0	0	0	0	0
Equity capital	3,750	3,700	3,660	3,660	3,660
Reserves & surplus	0	0	0	0	0
Shareholders' fund	847,490	871,080	898,460	1,126,296	1,382,272
Total liab. and equities	1,208,990	1,307,590	1,415,140	1,566,644	1,865,666
Cash and cash eq.	86,460	68,580	124,880	92,902	285,810
Accounts receivables	305,320	300,790	340,740	418,520	466,349
Inventories	0	0	0	0	0
Other current assets	239,510	295,170	247,870	358,731	399,728
Investments	273,760	318,440	362,180	362,180	362,180
Net fixed assets	198,410	196,690	196,150	190,625	199,032
CWIP	0	0	0	0	0
Intangible assets	19,930	22,780	28,880	28,880	28,880
Deferred tax assets, net	28,280	39,310	37,080	37,080	37,080
Other assets	57,320	65,830	77,360	77,725	86,608
Total assets	1,208,990	1,307,590	1,415,140	1,566,644	1,865,666
Cash Flows					
Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Cash flow from operations	328,975	372,880	398,330	192,644	450,157
Capital expenditures	(119,970)	(38,930)	(29,490)	(43,646)	(48,634)
Change in investments	(75,780)	44,680	(15,220)	0	0
Other investing cash flows	36,680	24,970	27,000	29,403	27,884
Cash flow from investing	(159,070)	30,720	(17,710)	(14,243)	(20,749)
Equities issued/Others	0	(259,499)	0	0	0
Debt raised/repaid	0	0	(14,170)	0	0
Interest expenses	0	0	(6,980)	0	0
Dividends paid	(155,685)	(161,981)	(133,170)	(210,379)	(236,500)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(155,685)	(421,480)	(154,320)	(210,379)	(236,500)
Chg in cash & cash eq. Closing cash & cash eq.	14,220	(17,880)	226,300	(31,978)	192,908

Per Share					
Y/E 31 Mar (Rs)	FY20A	FY21A	FY22E	FY23E	FY24E
Reported EPS	86.2	90.9	103.6	118.1	132.8
Adjusted EPS	86.2	90.9	103.6	118.1	132.8
Dividend per share	34.5	36.4	41.4	47.2	53.1
Book value per share	225.8	235.4	242.8	304.4	373.6
Valuations Ratios					
Y/E 31 Mar (x)	FY20A	FY21A	FY22E	FY23E	FY24E
EV/Sales	8.8	8.4	7.2	6.3	5.7
EV/EBITDA	32.8	29.7	26.1	22.8	20.3
Adjusted P/E	42.9	40.6	35.7	31.3	27.8
P/BV	16.4	15.7	15.2	12.1	9.9
DuPont Analysis					
Y/E 31 Mar (%)	FY20A	FY21A	FY22E	FY23E	FY24E
Tax burden (Net profit/PBT)	76.5	74.8	74.2	74.3	73.6
Interest burden (PBT/EBIT)	109.5	105.9	106.7	105.3	104.4
EBIT margin (EBIT/Revenue)	24.6	25.9	25.3	25.6	26.3
Asset turnover (Rev./Avg TA)	133.1	130.5	140.9	146.4	141.7
Leverage (Avg TA/Avg Equity)	1.4	1.5	1.5	1.5	1.4
Adjusted ROAE	37.0	39.2	43.3	43.2	39.2
Ratio Analysis					
Y/E 31 Mar	FY20A	FY21A	FY22E	FY23E	FY24E
YoY growth (%)					
Revenue	7.2	4.6	16.8	13.8	11.4
EBITDA	6.6	10.5	14.0	14.6	11.9
Adjusted EPS	2.6	5.5	13.9	14.0	12.4
Profitability & Return ratios (%)					
EBITDA margin	26.8	28.4	27.7	27.9	28.0
EBIT margin	24.6	25.9	25.3	25.6	26.3
Adjusted profit margin	20.6	20.5	20.0	20.0	20.2
Adjusted ROAE	37.0	39.2	43.3	43.2	39.2
ROCE	35.8	37.6	42.3	43.0	41.8
Working capital days (days)					
Receivables	67	67	61	63	66
Inventory	0	0	0	0	(
Payables	86	103	108	96	83
Ratios (x)					
Gross asset turnover	10.1	8.3	9.8	11.3	12.5

Adjusted debt/equity 0.0 0.0

Source: Company, BOBCAPS Research | Note: TA = Total Assets

2.4

NA

2.0

NA

1.7

NA

(0.1)

2.5

NA

0.0

3.0

NA

(0.2)

Current ratio

Net interest coverage ratio



Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): TATA CONSULTANCY SERVICES (TCS IN)



 $B-Buy,\,H-Hold,\,S-Sell,\,A-Add,\,R-Reduce$

Rating distribution

As of 31 March 2022, out of 116 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 65 have BUY ratings, 31 have HOLD ratings, 5 are rated ADD*, 1 is rated REDUCE* and 14 are rated SELL. One company rated ADD has been an investment banking client in the last 12 months. (*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years.

BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

TATA CONSULTANCY SERVICES



This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

ROBCAPS or its associates may have material conflict of interest at the time of publication of this research report

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.